Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  10/16/2009
 
Trade Name:  CERVARIX
 
Generic or Proper Name (*):  Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant*
 
Indications Studied:  Prevention of genital warts caused by HPV 16 and 18
 
Therapeutic Category:  Preventive Vaccine
 
Ages Studied:  10-25 years
 
Study #:  2
 
Study Type:  Safety/Immunogenicity
 
Study Design:  Single-Blind/Double-Blind/Uncontrolled
 
No Centers:  17
 
No Countries:  6
 
BPCA(B), PREA(P):  P
 
-
-